Covid-19 roundup: As AstraZeneca deals with vaccine woes, US turns attention to its antibody treatment; Moderna doses first kids in pediatric vaccine study
As countries around the world halt the distribution of AstraZeneca’s Covid-19 vaccine due to reports of blood clots, the US is more focused on the pharma’s antibody treatment.
The US has secured half a million more doses of AstraZeneca’s long-acting antibody combo AZD7442, building on an initial 100,000-dose deal struck back in October, the company said on Tuesday. AstraZeneca also has a separate agreement to supply the Department of Defense with 100,000 doses, bringing the US’ total supply order to 700,000 doses in 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.